Altogether, these observations, along with several recent preclinical studies combining CDK4/6i with CPI28–32, suggest that biomarker-selectable subsets of patients from mUC, NSCLC, and RCC may also benefit from combination therapy targeting both PD-(L)1 and CDK4/6 axes simultaneously. Here, CDK4 is linked to renal cell carcinoma.